Goodwin
Elizabeth Mulkey
- Deals
- 5
- Latest
- Jun 2026
- Most deals in
- Biotech
Firm
- Goodwin Law firm · 2026 · 5 deals
Often works with
- Arman Oruc 3 deals together
- Sarah Solomon 2 deals together
- Kingsley L. Taft 2 deals together
- Dasol Lee 2 deals together
- Daniel Karelitz 2 deals together
- Danielle Fong 2 deals together
- Gozde Guckaya 2 deals together
- Dan Karelitz 2 deals together
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
| Jun 2026 | Parabilis Medicines | – | – | Placement | Legal adviser to the issuer | Completed | 75.0 | Biotech+1 | Parabilis Medicines placement |
| May 2026 | Perfuse Therapeutics | – | Bayer | Acquisition | Legal adviser to Perfuse Therapeutics (target) | Announced | 300.0 | Biotech+2 | Bayer acquisition of Perfuse Therapeutics |
| May 2026 | LimmaTech Biologics AG | – | Eli Lilly and Company | Acquisition | Legal adviser to LimmaTech Biologics AG (target) | Pending | 780.0 | Biotech | Eli Lilly and Company acquisition of LimmaTech Biologics AG |
| Apr 2026 | Worldwide rights to Kenalog | Bristol-Myers Squibb | Subsidiary of Piramal Pharma | Asset sale | Legal adviser to subsidiary of Piramal Pharma (acquirer) | Announced | 35.0 | Pharma | Subsidiary of Piramal Pharma acquisition of Worldwide rights to Kenalog |
| Apr 2026 | Tubulis | EQT Life Sciences (LSP 7 fund) | Gilead Sciences | Acquisition | Legal adviser to Tubulis (target) | Announced | 3,150.0 | Biotech+2 | Gilead Sciences acquisition of Tubulis |
Deals where Elizabeth Mulkey is named on the firm's deal team, by the firm or the press.